Home / Peptides

Tesamorelin

Also called: Egrifta

By The Health Stacks Research TeamUpdated July 28, 2026

Tesamorelin is an FDA-approved peptide (marketed as Egrifta) classified as a GHRH (Growth Hormone Releasing Hormone) analog.

It is primarily used for reducing visceral fat and stimulating lipolysis (fat breakdown), specifically targeting HIV lipodystrophy.

It is considered a well-studied compound with a robust safety profile, scoring an 8/10 on safety indexes. It should be stored under refrigeration (2–8°C) and protected from light, lasting up to 28 days after reconstitution.

Research-stageEarly-stage — studied in cell or animal models, not yet tested in humans. Low confidenceBelow 40 — limited or lower-quality sourcing. Verify independently before relying on this.
Where to Source Tesamorelin
Tested purity COA available Fast shipping

What Tesamorelin Helps With

The benefits people report — backed by research.

Weight management (31)

Reduction of visceral adipose tissue 95/100· 10 srcVisceral Adipose Tissue Reduction 95/100· 4 srcVisceral fat reduction 95/100· 3 srcIncreases lean body mass 95/100· 2 srcIncreased lean body mass 85/100· 2 srcSignificantly reduces visceral adipose tissue 95/100Reduces trunk fat and waist circumference 95/100Significantly decreases visceral adipose tissue 95/100Significant visceral adipose tissue reduction 95/100Reduction of excess visceral adipose tissue 95/100Significant reduction in visceral adipose tissue 95/100Reduction of excess abdominal fat 95/100Preferential reduction of visceral adipose tissue 90/100Improves trunk fat and waist circumference body composition measures 90/100Reduces visceral fat 90/100Lean Body Mass Increase 90/100Body Recomposition 90/100Enhanced lipolysis 90/100Preservation of lean body mass 90/100Improvement in body image perception 85/100Improvement in adipose tissue quality 85/100Body Composition Improvements 85/100Improves adipose tissue quality independent of fat quantity changes 85/100Increases lean body mass and IGF-1 levels within physiological range 85/100Preservation and Increase of Lean Body Mass 85/100Improves body image parameters 85/100Appetite Stimulation 85/100Selective reduction of visceral adipose tissue 85/100Preservation of subcutaneous fat deposits 85/100Visceral fat reduction and lipolysis 72/100Boosts blood flow to injuries 60/100

Reproductive & hormonal (21)

IGF-1 Elevation 95/100· 2 srcIGF-1 Level Elevation 95/100Increase in IGF-1 and Growth Hormone activity 95/100Growth velocity increase 95/100Augmentation of endogenous growth hormone and IGF-1 secretion 95/100Stimulation of pulsatile growth hormone secretion 90/100Stimulates endogenous GH release in pulsatile patterns 90/100Physiological GH/IGF-1 Restoration Without HPA Suppression 90/100Elevated IGF-1 levels 90/100Stimulates pituitary GH release and raises IGF-1 90/100GH release via GHRH-receptor activation 90/100Elevation of IGF-1 85/100Preservation of natural pulsatile GH release and hypothalamic-pituitary feedback loop 85/100Promotes pulsatile release of endogenous growth hormone from pituitary cells 85/100Pulsatile GH release 85/100Restoration of Physiological GH Pulsatility in GH Deficiency 80/100IGFBP-3 extends IGF-1 half-life from minutes to 12 to 16 hours via ternary complex 72/100Stimulation of endogenous growth hormone release 72/100Activation of GH/IGF-1 axis 70/100Preserves natural GH pulsatility 60/100Synergistic growth hormone release when stacked with Ipamorelin 60/100

Antimicrobial & antiviral (17)

Reduction of visceral adipose tissue in HIV-associated lipodystrophy 95/100· 3 srcSupports liver health 90/100· 3 srcReduces visceral adipose tissue in HIV-associated lipodystrophy 95/100· 2 srcPrevention of fibrosis progression in HIV-associated NAFLD 95/100· 2 srcDecreases visceral adipose tissue in people living with HIV 95/100Reduction of excess visceral adipose tissue in HIV-associated lipodystrophy 95/100Visceral fat reduction in HIV-associated lipodystrophy 95/100Reduces excess visceral abdominal fat in HIV lipodystrophy 90/100Significant VAT reduction over 26-52 weeks in pivotal trials (FDA-approved indication)Reduction of excess abdominal fat in HIV-associated lipodystrophy 90/100Reduces visceral adipose tissue in ART-treated HIV patients 90/100Reduces visceral adipose tissue 90/100Decrease visceral fat buildup in HIV-associated lipodystrophy 90/100Reduction of hepatic fat fraction in HIV-associated NAFLD/NASH 85/100Reduces visceral fat in HIV-associated lipodystrophy 85/100Reduction of visceral fat in HIV-associated lipodystrophy 85/100Reduces abdominal fat in HIV patients with lipodystrophy 80/100Supports brain health 80/100

Renal & hepatic (12)

Supports liver health 95/100· 2 srcNAFLD Improvement 95/100Modulation of hepatocellular carcinoma prognosis gene sets 95/100Reduction of hepatic fat fraction in NAFLD 90/100Reduces hepatic fat percentage 90/100Hepatic Steatosis Reversal 90/100Reduction of hepatic fat 90/100Reduction in hepatic fat content 85/100Reduction in hepatic fat fraction in NAFLD/NASH 85/100Amelioration of hepatic steatosis 85/100Reduction of hepatic fat content in NAFLD 85/100Reduces hepatic fat fraction in NAFLD 80/100

Performance & recovery (11)

IGF-1 Elevation 95/100Stimulates pituitary release of growth hormone and raises IGF-1 90/100GH-axis support / GH release stimulation 90/100Growth hormone release 90/100Increases IGF-1 levels 90/100Stimulate release of growth hormone 90/100IGF-1 Axis Restoration 85/100Acute GH Release Potency 85/100GH secretagogues stimulate endogenous GH release 72/100Tesamorelin, sermorelin, and CJC-1295/ipamorelin raise both IGF-1 and IGFBP-3 72/100Larger GH pulse when paired with Ipamorelin 60/100

Glycemic & metabolic (11)

Helps regulate blood sugar 90/100Improvement in triglyceride levels and cholesterol ratios 90/100Improved triglycerides and cholesterol ratios 90/100Improvement in triglycerides and lipid parameters 85/100Early shifts in IGF-1 and metabolic markers 85/100Improvement in metabolic profile 85/100Improved Metabolic Markers 85/100Better Glucose Metabolism 80/100Fasting-glucose shift 80/100Improvements in lipid profile and metabolic markers 80/100Improves lipid profiles 75/100

Neuroprotection & cognitive (8)

Supports brain health 90/100Improved working memory and increased hippocampal volume 85/100Improves executive function, verbal memory and working memory 85/100Improvement in executive function and verbal memory 85/100Improves body image and patient-reported outcomes 82/100Improvements in body image distress reported in trialsModest improvements in executive function and verbal memory 80/100Augmentation of peripheral nerve regeneration 75/100Neuroprotection 75/100

Cardiovascular & vascular (7)

Improved lipid profiles 90/100· 2 srcImprovement in triglyceride and cholesterol levels 90/100Improves triglycerides and total cholesterol 90/100Improvement in cardiometabolic markers 90/100Improvement in Triglycerides and Cholesterol Ratios 90/100Boosts blood flow to injuries 90/100Reduction of plasma VEGFA 90/100

Musculoskeletal (3)

Increased IGF-1 levels 95/100· 2 srcSpeeds muscle recovery 90/100Increased protein synthesis 80/100

Anti-inflammatory (3)

Reduction of plasma CSF1 90/100Reduces inflammation 85/100Reduction in inflammatory markers 80/100

Tissue & wound healing (2)

Reduces inflammation 95/100Fat burning 85/100

Immune modulation (2)

Strengthens immunity 90/100Reduces visceral fat cell volume by an average of 15% via lipolysis activation 80/100

Anti-fibrotic (2)

Supports liver health 90/100Reduction of plasma TGFB1 90/100

Other Benefits (10)

Stimulation of Growth Hormone and IGF-1 release 90/100Upregulates IGF-1 levels by ~122% from baseline, promoting protein synthesis, cell proliferation, and repair 85/100Synergistic GH elevation 72/100Stimulation of pituitary growth hormone release in natural rhythm 72/100Somatostatin Override 60/100Spares peripheral limb fat and prevents worsening of lipoatrophy 85/100Improves body image and health-related quality of life 80/100Improves mitochondrial function 80/100IGFBP-3 has pro-apoptotic effects and modulates cell proliferation independently of IGF-1 72/100Improves sleep 60/100
Tesamorelin — strength

How People Use It

Under the skin

  • 2 mg, 1× per day — Reduce excess visceral fat in HIV-associated lipodystrophy
  • 3 mg/kg orally once daily in dogs and 2 mg/kg once daily in cats

For research purposes only. Not medical advice. Talk to a doctor before use.

Get Tesamorelin for Your Research

Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.

Find Tesamorelin Research Suppliers
Tested purity COA available Fast shipping
Technical Details & Research (click to expand)

Mechanism of Action

Tesamorelin is an N-terminally modified synthetic analog of growth hormone releasing hormone (GHRH) that stimulates pituitary GH release, raising IGF-1 and selectively mobilizing visceral adipose tissue. It is FDA-approved (Egrifta) to reduce excess visceral abdominal fat in HIV-associated lipodystrophy.

Known Side Effects

All Dosing Protocols

Egrifta (FDA-approved) — SubQ · 2 mg · 1×/day 90/100
GHRH 1-29 — SubQ 95/100

Research Citations (148)

History & Milestones

Key moments in Tesamorelin’s research and regulatory timeline — sourced and dated.

  1. Spotlight on tesamorelin in HIV-associated lipodystrophyPublicationJan 1, 2011
    88/100↗ source

Free: The Peptide Stack Cheat-Sheet

The most-used peptide combinations, dosing at a glance, and what the research says — one page, one email.

No spam. Unsubscribe anytime.

Related on The Health Stacks

Explore by goal

Growth Hormone Secretagogues

Related peptides

CJC-1295Ipamorelin